Urea

NAFLD

Michael Ohliger, MD PhDSmall moleculeDormant

D

30/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 15/ 100
Competitive Position: 81/ 100

Competitive context

28 Active assets in the NAFLD cohort.

Asset / Sponsor	Phase	Rating
Empagliflozin Justin Ryder	Phase 4	BBB
Saroglitazar Zydus Lifesciences Limited	Phase 4	BB
UMBELLATINE China National Center for Cardiovascular Diseases	Phase 4	BB
Rybelsus Zagazig University	Phase 4	BB
Lansoprazole Children's Mercy Hospital Kansas City	Phase 4	BB

View all 50 →

Same molecule, other indications

Urea is also rated in:

radiodermatitisDormant

BB

Indicative ·

69 / 100

hepatocellular carcinomaDormant

B

Indicative ·

63 / 100

cancer of unknown primary siteDormant

B

Indicative ·

62 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.